EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Differences in anti‐amyloid therapy eligibility assessment based on use of the SWI versus GRE sequence

Camilo Bermudez iD, Jay J Pillai, Brian J Burkett, Jennifer S McDonald, Derek R Johnson, Heather J Wiste, Stephen D Weigand, Clifford R Jack, Prashanthi Vemuri, Ronald C Petersen, Jonathan Graff-Radford, Vijay K Ramanan and 1 more

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)

DOI: 10.1002/dad2.70524 ↗

At a glance

Journal article in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, published online on 2026-10-28. Written by Camilo Bermudez and 12 co-authors. Institution: Department of Neurology Mayo Clinic Rochester Minnesota USA. 15 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

The number of microhemorrhages (mHs) increases risk of amyloid‐related imaging abnormalities (ARIAs) in those undergoing anti‐amyloid treatments for Alzheimer's disease. It is unclear whether using different magnetic resonance imaging (MRI) sequences to detect mH would alter treatment decisions.

Methods

We retrospectively analyzed 55 adults (mean age 72.1 ± 7.1 years) evaluated for cognitive concerns who had MRI exams including both susceptibility‐weighted imaging (SWI) and gradient echo (GRE) sequences. Three neuroradiologists independently identified and then reached consensus on mH detection. Participants were classified into mH burden categories (none, 1, 2–4, ≥ 5).

Results

Readers identified 83 mHs (mean 1.51) on SWI versus 54 (mean 0.98) on GRE. Burden categories agreed in 34 (61.8%) participants, was higher on SWI in 17 (30.9%) participants, and higher on GRE in 4 (7.3%) participants, Conclusions Readers on average identified more mHs on SWI than GRE, altering risk categories. Prospective studies are needed to establish SWI‐based safety thresholds for anti‐amyloid therapies.

Subjects

Author keywords

anti‐amyloid therapiesgradient echomicrohemorrhagessusceptibility‐weighted imaging

Authors and institutions

  • Department of Neurology Mayo Clinic Rochester Minnesota USA.
  • Department of Radiology Mayo Clinic Rochester Minnesota USA.
  • Department of Neurosurgery Johns Hopkins University School of Medicine Baltimore Maryland USA.
  • Department of Quantitative Health Science Mayo Clinic Rochester Minnesota USA.

ORCID profiles: Camilo Bermudez, Petrice M Cogswell

Cite

APA

Bermudez, C., Pillai, J. J., Burkett, B. J., McDonald, J. S., Johnson, D. R., Wiste, H. J., Weigand, S. D., Jack, C. R., Vemuri, P., Petersen, R. C., Graff-Radford, J., Ramanan, V. K., & Cogswell, P. M. (2026). Differences in anti‐amyloid therapy eligibility assessment based on use of the SWI versus GRE sequence. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(4). https://doi.org/10.1002/dad2.70524

Vancouver

Bermudez C, Pillai JJ, Burkett BJ, McDonald JS, Johnson DR, Wiste HJ, et al. Differences in anti‐amyloid therapy eligibility assessment based on use of the SWI versus GRE sequence. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(4). doi:10.1002/dad2.70524

BibTeX
@article{Bermudez2026,
  author = {Bermudez, Camilo and Pillai, Jay J and Burkett, Brian J and McDonald, Jennifer S and Johnson, Derek R and Wiste, Heather J and Weigand, Stephen D and Jack, Clifford R and Vemuri, Prashanthi and Petersen, Ronald C and Graff-Radford, Jonathan and Ramanan, Vijay K and Cogswell, Petrice M},
  title = {Differences in anti‐amyloid therapy eligibility assessment based on use of the SWI versus GRE sequence},
  journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
  year = {2026},
  volume = {18},
  number = {4},
  doi = {10.1002/dad2.70524}
}
Start for free →